SHANGHAI, Oct 21, 2024 – (ACN Newswire) – Everest Medicines (HKEX 1952.HK, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration (TFDA) has approved NEFECON® indicated “to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression1”. There are no restrictions on initial proteinuria levels in the approved indication. This marks the expansion o…
